Navigation Links
Abt Associates Ranked One of Top 20 U.S. Market Research Firms
Date:7/29/2008

(Abt Bio-Pharma Solutions, Inc.); New York, New York (Abt SRBI); and in Africa, Asia, Central Asia, Europe, Latin America, and the Middle East.


'/>"/>
SOURCE Abt Associates
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. NSF International Acquires David Begg Associates
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
5. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
6. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
7. Halogen Receives High Ratings from Bersin & Associates - Company recognized as a market leader, and receives praise for outstanding customer satisfaction
8. QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index
9. Lambert, Edwards & Associates Named Agency of Record for The West Michigan Science & Technology Initiative
10. QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes (As Revised)
11. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4
Other Biology Technology:measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 2measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 3measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 4measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 5measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 6measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 7measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 8measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 9measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 10measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 11measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 12measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 13measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 14measuring cell proliferation with SpectraMax M5, M2 and Gemini microplate readers using the CyQUANT Cell Proliferation Assay 15Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 2Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 3Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 4Introducing,GenElute HP,Endotoxin-Free Plasmid,Maxiprep Kit 5Protocol for GenomePlex Whole Genome Amplification from Plant 2Protocol for GenomePlex Whole Genome Amplification from Plant 3Protocol for GenomePlex Whole Genome Amplification from Plant 4Protocol for GenomePlex Whole Genome Amplification from Plant 5Protocol for GenomePlex Whole Genome Amplification from Plant 6
Breaking Biology News(10 mins):Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 2Penn, Georgia collaboration awarded $14.6 million to expand pathogen database 3Successful stem cell therapy for treatment of eye disease 2Breakthrough in monitoring tropical deforestation announced in Copenhagen 2Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 1Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 2Natural Pepper Skin Sprays Stop Any Itch In Minutes Without Burning 60740 3Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 1Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 2Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 3Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 4Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 5Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 6Cell Therapeutics Decreases Net Loss for Nine Month Period in 2009 Compared to Same Period in 2008 by 45 25 60735 7Regences Social Media Web Site Gets a Facelift 60731 1Regences Social Media Web Site Gets a Facelift 60731 2